The Alabama Board of Medical Examiners issued an official warning Tuesday, directing physicians not to prescribe non-FDA-approved “research-grade” peptides because of patient safety concerns.
The board noted that public interest in unregulated peptides has grown partly because of social media and online wellness trends.
“Patients are increasingly exposed to online marketing that can blur the line between legitimate medicine and unregulated products. Many patients may not realize research-grade peptides are not approved for human use,” Dr. Max Rogers, chair of the Board of Medical Examiners, said.
“When a substance has not gone through FDA review, there is no reliable way to verify what it actually is, how it was manufactured or what risks it may pose,” Rogers said. “Our responsibility is to protect patients and ensure medical professionals uphold the high standards required under Alabama law.”
While the Trump administration has indicated that it may ease restrictions on research-grade peptide injections in the near future, the drugs are not currently approved by the Food and Drug Administration and are not subject to oversight for safety, effectiveness, manufacturing quality or consistency.
Despite these risks, unregulated peptides have gained attention because of the influence of social media personalities and the so-called “looksmaxxing” community, where teenage boys and young men go to extreme lengths to achieve physical ideals. These influencers advertise peptide use as a method for improving physical appearance without disclosing the potential health risks of using unregulated medication.
Additionally, the rise of FDA-approved GLP-1 weight-loss medications, such as Ozempic and Wegovy, may be partly responsible for increased interest in experimental peptides. However, while those drugs have undergone years of human trials and remain subject to federal regulations, research-grade peptides lack comparable long-term safety data and are not approved for human consumption.
In its alert, the board reemphasized that all physicians in Alabama must purchase prescription drugs and ingredients from properly permitted entities and that all medications provided to patients must meet prescription-quality standards.
Alabama law prohibits licensed medical professionals from supplying non-FDA-approved research-grade peptides to patients, even if the professional provides the patient with a consent form or waiver describing the substance as “research-grade.”
The board said it remains committed to protecting the health and safety of Alabama patients and expects all practitioners to comply fully with state law and professional standards of care.
